Shiva Pharmachem files DRHP for its Rs. 900 crore IPO
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Construction will begin this year with the new capacity anticipated by 2025
Unani Medicine facilities to be upgraded at Hyderabad, Chennai, Lucknow, Silchar and Bengaluru
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Dozee plans to further tap over 2,000 hospitals in more than 100 districts
Subscribe To Our Newsletter & Stay Updated